121 results about "Nerve activity" patented technology

A method and apparatus for treatment of cardiac and renal diseases associated with the elevated sympathetic renal nerve activity by implanting a device to block the renal nerve signals to and from the kidney. The device can be a drug pump or a drug eluding implant for targeted delivery of a nerve-blocking agent to the periarterial space of the renal artery.

This invention provides methods for mapping and ablating renal nerves to treat disease caused by systemic renal nerve hyperactivity, e.g. hypertension, heart failure, renal failure and diabetes. Also provided are catheters for performing the mapping and ablating functions.

A method and an apparatus for treating a patient suffering from, or at risk for, a condition mediated by the inflammatory cytokine cascade, by electrically stimulating vagus nerve activity in an amount sufficient to inhibit the inflammatory cytokine cascade.

The invention provides a system and method for treating a subject having unwanted or overactive nerve activity. The method involves applying one or more of direct current, charge imbalanced time varying current and pulsatile current to a target nerve; and controlling the amplitude and the duration of the current such that there is a net charge delivered to the target nerve at a sufficient charge density to cause controlled ablation to the target nerve until unwanted or overactive nerve activity is reduced in one or both of the target nerve and a target body tissue innervated by the target nerve.

At least one of a plurality of disorders of a patient are treated where the disorders are associated with a gastrointestinal tract of a patient where the disorders are characterized at least in part by hyper-tonal vagal activity innervating at least one of a plurality of alimentary tract organs of the patient at an innervation site. The treatment includes applying a neural conduction block to a vagus nerve of the patient at a blocking site proximal to the innervation site. The neural conduction block is selected to at least partially block nerve impulses on the vagus nerve at the blocking site. A treatment apparatus has an electrically controllable neural conduction electrode adapted to be placed on a vagus nerve of a patient at a blocking site proximal to an innervation site.

Described herein are methods for treating a subject suffering from or at risk for a condition mediated by an inflammatory cytokine cascade, by electrically or mechanically stimulating vagus nerve activity in an amount sufficient to inhibit the inflammatory cytokine cascade.

Methods and devices to treat discogenic lumbar back pain are disclosed. Electrodes are implanted within the anterior epidural space of the patient. A pulse generator that is connected to the electrodes delivers electrical impulses to sympathetic nerves located within the posterior longitudinal ligament (PLL) of the lumbar spine and outer posterior annulus fibrosus of the intervertebral disc. In alternate embodiments, energy directed to nerves in the PLL may be from light or mechanical vibrations, or the nerves may be cooled. The electrodes may also be used diagnostically to correlate spontaneous nerve activity with spinal movement, fluctuations in autonomic tone and the patient's experience of pain. The electrodes may also be used to generate diagnostic evoked potentials. The diagnostic data are used to devise parameters for the therapeutic nerve stimulation. Automatic analysis of the data may be incorporated into a closed-loop system that performs the nerve stimulation automatically.

Methods, systems, and apparatus for detecting an epileptic event, for example, a seizure in a patient using a medical device. The determination is performed by providing an autonomic signal indicative of the patient's autonomic activity; providing a neurologic signal indicative of the patient's neurological activity; and detecting an epileptic event based upon the autonomic signal and the neurologic signal.

An intravascular catheter for nerve activity ablation and/or sensing includes one or more needles advanced through supported guide tubes (needle guiding elements) which expand to contact the interior surface of the wall of the renal artery or other vessel of a human body allowing the needles to be advanced though the vessel wall into the extra-luminal tissue including the media, adventitia and periadvential space. The catheter also includes structures which provide radial and lateral support to the guide tubes so that the guide tubes open uniformly and maintain their position against the interior surface of the vessel wall as the sharpened needles are advanced to penetrate into the vessel wall. Electrodes near the distal ends of the needles allow sensing of nerve activity before and after attempted renal denervation. In a combination embodiment ablative energy or fluid is delivered from the needles in or near the adventitia to ablate nerves outside of the media while sparing nerves within the media.

The present disclosure provides methods for improving drug efficacy in a patient having an obstructed airway in a lung. Such methods modulate nerve activity in the autonomic nervous system of a patient to reduce obstruction of an airway in a lung of the patient prior to administering a drug to the patient. These methods are especially useful in improving efficacies of bronchodilators in treating obstructive lung diseases, such as chronic obstructive pulmonary disease.

The present invention provides devices and methods for modulating or blocking renal sympathetic nerve activity by applying laser energy to the renal artery wall to effect ablation of the renal nerve or nerves. The devices and methods of the invention may be useful in the treatment of cardiovascular and renal disease resulting from hypertension. In addition the devices and methods of the invention may be useful for reducing reflex hypertension following cyclosporine administration after organ transplantation.

The present invention provides a self anchoring electrode for recording, measuring and/or stimulating nerve activity in nerves and/or nerve fascicles of the peripheral nervous system, and methods for using such a self anchoring electrode.

The present invention provides compositions and methods for ameliorating neurological or memory disorders and improving learning and cognition through the increase of cyclic AMP. Gilatides, peptides comprising the nine amino acid sequence (SEQ ID NO:1), and functional analogs thereof are disclosed to modulate neurological activity when administered to a subject. The methods of the invention can be used to prevent or treat neurological disorders as well as improve memory retention and acquisition. In addition, the invention can be used to modulate insulin levels and blood glucose. The invention includes pharmaceutical compositions comprising a therapeutically or prophylactically effective amount of a Gilatide peptide or a functional analog thereof.

The present invention provides a nerve monitoring device. The device includes a cannula, a sensor for monitoring the nerve and an alignment device. The cannula can be any surgical cannula, and is preferably an endotracheal tube. The sensor can be an electrode or other sensor that is capable of sensing nerve activity. The alignment device is a device that ensures that after insertion of the nerve sensor into a patient, the sensors are aligned to properly monitor the target nerve or muscle. The internal alignment device may communicate externally to surgeon by using electromagnetic energy as either a transmittor or a receiver. The mismatch of triangular laryngeal anatomy to circular cannula anatomy can be compensated for by a) altering the geometry (external shape) of the cannula and b) using soft, felt-like expandable electrodes. Rotational error can be compensated for by using a multi-electrode array wherein the optimized recording montage can be simply selected on the external recording device.

Some implementations provide a method for treating urological disorders in a patient, the method including: placing an introducer into a patient's body through an incision site on the patient's body, the patient suffering from an urological disorder; placing an implantable wireless device into an inner lumen of the introducer, the implantable wireless device suitable to fit into the inner lumen and configured to receive electromagnetic energy non-inductively from a source located outside the patient's body; through the inner lumen of the introducer, positioning the implantable wireless device adjacent to or near one or more excitable tissue in the patient, the one or more excitable tissue regulating a nerve activity associated with the urological disorder; and causing neural modulation of the one or more excitable tissue through one or more electrodes on the implantable wireless device.

An intravascular catheter for nerve activity ablation and/or sensing includes one or more needles advanced through supported guide tubes (needle guiding elements) which expand to contact the interior surface of the wall of the renal artery or other vessel of a human body allowing the needles to be advanced though the vessel wall into the extra-luminal tissue including the media, adventitia and periadvential space. The catheter also includes structures which provide radial and lateral support to the guide tubes so that the guide tubes open uniformly and maintain their position against the interior surface of the vessel wall as the sharpened needles are advanced to penetrate into the vessel wall. Electrodes at the distal ends of the guide tubes allow sensing of nerve activity before and after attempted renal denervation. In a combination embodiment ablative energy or fluid is delivered to ablate nerves outside of the media.

The invention provides easy handling and low cost-support equipment for measuring optical nerve-activity which is less stressful for subjects or doctors and the like. The support equipment, which provides light stimulation for subject eyes with its main body 10 fixed to the subject-head region and measures the subject optical nerve-activity, comprises a thin walled-main body 10 with a plurality of optical fibers 11 joined in the width direction; light emission regions 13a, 13b at least one of which is positioned in the main body aligned to the subject eye-position(s) and composed of a plurality of light leak parts 11c formed in peripheral surfaces of the optical fibers 11; and a connector 12a for connecting with a light emission device 12 providing light for each of the plurality of optical fibers.

An Electro Diagnostic Functional Assessment Unit (EFA-3) that is designed to wirelessly monitor muscle group activity and to provide treatment for humans and animals. The muscle groups include the body, fascial, cervical, thoracic, upper and lower extremities, lumbosacral, bladder, cardiac, and rectal. In large animals the muscle groups include torso, legs, neck and face. The EFA-3 simultaneously correlates the muscle activity EMG with cardiac activity, nerve activity, heart rate, blood flow and brain activity with range-of-motion, grip and pinch assessment and a functional assessment in humans. The EFA-3 is operated by proprietary software (78) which provides testing protocols by utilizing a set of wireless sensor(s) (14-40) that are interchangeable and rechargeable. The treatment includes ultrasound, heat, cold, massage and electrical stimulation.

Devices, systems and methods for applying electrical impulse(s) to one or more selected nerves are described. An electrical stimulator is introduced through a to a target location within, adjacent to, or in close proximity with, the carotid sheath. The stimulator has an antenna that allows it to be powered solely by far-field or approximately plane wave electromagnetic radiation, having frequencies in the range of 0.3 to 10 GHz. Electrical impulses are applied through the stimulator to a vagus nerve to stimulate, block or otherwise modulate activity of the nerve and treat the patient's condition. The stimulator uses an adjustable number of fixed voltage (or fixed current) pulses with fixed duration to elicit desired changes in nerve response, the timing of which are controlled by an external power transmitter and controller.

A medication delivery device for treatment of a pulmonary disorder in a patient includes an elongate member, an expandable member is coupled to a distal end of the elongate member, and an agent delivery portion coupled to an external surface of the expandable member. The agent delivery portion includes an agent that disrupts nerve activity.